Evogliptin

DB12625InvestigationalSmall molecule

Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.

Chemical structure of Evogliptin
Mechanism
Curator reviewed
Formula / weight
C19H26F3N3O3 · 401.43 g/mol (avg)
Code names
DA-1229

Resolves to

Compound
UNII09118300L7CAS1222102-29-5ChEMBLCHEMBL1779710PubChem25022354
Clinical / RWD
ATCA10BD22ATCA10BH07
Structure
InChIKeyLCDDAGSJHKEABN-MLGOLLRUSA-NSMILESCC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F
Targets
P27487DPP4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
657Drug interactionsStructured to mechanism, not free text
Sign in
23Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2ATC codesIncluding every combination product, plus 7 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Evogliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In